

Novel 1,3,4-Thiadiazole Derivatives: Design, Synthesis, Characterization and Anticancer Evaluation – A Review

Mane Yogita L.^{1,*}, Vishal Babar², Sudarshan Nagrale³

Abstract

Cancer remains one of the leading causes of mortality worldwide despite significant advances in diagnosis and treatment. The clinical usefulness of many anticancer drugs is often restricted by toxicity, poor selectivity, and the emergence of drug resistance. These limitations have encouraged the search for novel heterocyclic compounds with improved therapeutic efficacy and safety. Among these, the 1,3,4-thiadiazole scaffold has gained considerable attention because of its favorable physicochemical characteristics, metabolic stability, and ability to interact with multiple biological targets. Various 1,3,4-thiadiazole derivatives have demonstrated potent anticancer activity by inducing apoptosis, arresting the cell cycle, inhibiting angiogenesis, and modulating important signaling pathways involved in tumor progression. Structural modification and molecular hybridization have further enhanced their pharmacological potential. This review summarizes recent advances in the chemistry, design strategies, synthetic approaches, structure–activity relationships, and anticancer applications of 1,3,4-thiadiazole derivatives. In addition, current challenges and future perspectives associated with the development of thiadiazole-based anticancer agents are briefly discussed.

Keywords: 1,3,4-Thiadiazole, anticancer agents, medicinal chemistry, drug design, structure–activity relationship, cancer therapy

INTRODUCTION

Cancer is a multifactorial disease characterized by uncontrolled cell proliferation, abnormal cellular differentiation, and the ability of malignant cells to invade surrounding tissues and spread to distant organs. Although remarkable progress has been achieved through surgery, radiotherapy, chemotherapy, targeted therapy, and immunotherapy, the effectiveness of current treatment options is often limited by severe adverse effects, insufficient selectivity, poor bioavailability, and the development of multidrug resistance. These challenges continue to drive the discovery of safer and more effective anticancer agents [1, 2].

*Author for Correspondence

Mane Yogita L.

E-mail: maneyogita27@gmail.com

¹Research Scholar, Department of Pharmacy, Dattakala College of Pharmacy, Pune, Maharashtra, India

²Professor, Department of Pharmacy, Dattakala College of Pharmacy, Pune, Maharashtra, India

³Professor, Department of Pharmacy, Dattakala College of Pharmacy, Pune, Maharashtra, India

Received Date: July 11, 2026

Accepted Date: July 20, 2026

Published Date: July 21, 2026

Citation: Mane Yogita L., Vishal Babar, Sudarshan Nagrale. Novel 1,3,4-Thiadiazole Derivatives: Design, Synthesis, Characterization and Anticancer Evaluation – A Review. Research & Reviews: A Journal of Drug Design & Discovery. 2026; 13(2): 42–49p.

Heterocyclic compounds play a central role in medicinal chemistry because of their broad spectrum of biological activities. Among them, the 1,3,4-thiadiazole nucleus has emerged as an important pharmacophore owing to its aromatic nature, favorable electronic properties, and structural versatility. The presence of sulfur and nitrogen atoms within the five-membered ring facilitates strong interactions with various enzymes, receptors, and nucleic acids, making these compounds attractive candidates for drug development [3–5].

Several 1,3,4-thiadiazole derivatives have exhibited promising anticancer activity against

different human cancer cell lines, including breast, lung, liver, cervical, and colon cancers. Their biological effects are mediated through multiple mechanisms such as apoptosis induction, inhibition of angiogenesis, cell-cycle arrest, enzyme inhibition, and interference with intracellular signaling pathways. Furthermore, molecular hybridization with pharmacologically active scaffolds – such as quinoline, coumarin, benzimidazole, pyrazole, and triazole – has significantly improved their potency and target selectivity [1, 6–17].

Considering the increasing interest in thiadiazole-based therapeutics, this review provides a concise overview of their chemistry, design strategies, synthesis, structure–activity relationship, and anticancer potential, highlighting their importance as promising lead molecules for future anticancer drug discovery [1, 2].

The general structure and numbering of the 1,3,4-Thiadiazole nucleus are illustrated in Figure 1.




Figure 1. General structure and numbering of 1,3,4-Thiadiazole.

CHEMISTRY OF 1,3,4-THIA DIAZOLE

1,3,4-Thiadiazole is an important sulfur- and nitrogen-containing heterocyclic scaffold that has attracted considerable attention in medicinal chemistry because of its diverse pharmacological properties. Among the four known thiadiazole isomers, the 1,3,4-thiadiazole nucleus is the most extensively investigated due to its excellent chemical stability, aromatic character, and broad therapeutic potential [2–5].

The five-membered aromatic ring contains two nitrogen atoms, one sulfur atom, and two carbon atoms, providing a unique electronic environment that promotes strong interactions with biological macromolecules such as enzymes, receptors, and nucleic acids. These characteristics contribute to favorable metabolic stability, enhanced receptor affinity, and improved pharmacological performance [3–5].

The C-2 and C-5 positions of the thiadiazole ring are particularly suitable for structural modification.

Substitution at these positions allows optimization of lipophilicity, electronic properties, biological activity, and pharmacokinetic behavior. Consequently, numerous substituted 1,3,4-thiadiazole derivatives have been developed with enhanced therapeutic efficacy [1, 4–7, 14, 15].

Another important feature of the 1,3,4-thiadiazole scaffold is its ability to function as a bioisostere for several aromatic and heteroaromatic systems. Such substitution often improves metabolic stability, receptor binding, and overall biological activity. Because of these advantages, 1,3,4-thiadiazole has become an important pharmacophore in the design of novel anticancer agents [3–5, 15].

The chemical structure and numbering of the 1,3,4-Thiadiazole scaffold are shown in Figure 2.




Figure 2. Structure and chemical numbering of 1,3,4-Thiadiazole.

DESIGN STRATEGIES OF NOVEL 1,3,4-THIA DIAZOLE DERIVATIVES

The development of 1,3,4-thiadiazole-based anticancer agents mainly relies on rational drug design aimed at improving potency, selectivity, and pharmacokinetic properties. Structural modification at the C-2 and C-5 positions remains one of the most effective strategies for enhancing biological activity. The incorporation of electron-withdrawing substituents, including halogens, nitro, and trifluoromethyl groups, generally improves target binding and cytotoxic potential, whereas electron-donating groups – such as methoxy, hydroxy, and amino groups – may enhance solubility and receptor selectivity [1, 5, 6, 10–15].

Molecular hybridization has further expanded the therapeutic value of the thiadiazole scaffold. Combining 1,3,4-thiadiazole with other bioactive moieties, including quinoline, coumarin, benzimidazole, pyrazole, triazole, and chalcone, has produced hybrid molecules with superior anticancer activity and broader mechanisms of action [1, 8, 10, 15–17].

Another widely adopted approach is bioisosteric replacement, in which the thiadiazole ring substitutes conventional aromatic systems to improve metabolic stability, membrane permeability, and receptor affinity while reducing undesirable toxicity [3–5].

Recent research has also focused on target-oriented drug design, leading to the development of thiadiazole derivatives capable of inhibiting key molecular targets involved in cancer progression, including EGFR, VEGFR, HDACs, CDKs, PI3K, topoisomerases, and tubulin. These strategies have significantly strengthened the potential of 1,3,4-thiadiazole derivatives as promising lead compounds for future anticancer drug development [1, 6–12, 14–18].

SYNTHESIS OF 1,3,4-THIADIAZOLE DERIVATIVES

The synthesis of 1,3,4-thiadiazole derivatives has been extensively explored because of their significant medicinal importance. Various synthetic approaches have been developed to obtain structurally diverse compounds with improved biological activity. Among these, cyclization of acyl thiosemicarbazide intermediates remains the most commonly employed and reliable method for preparing substituted 1,3,4-thiadiazoles [4–7, 14, 15].

In the conventional synthetic route, carboxylic acid derivatives are first converted into acid hydrazides, which subsequently react with thiosemicarbazide to produce acyl thiosemicarbazide intermediates. Cyclization under dehydrating conditions using reagents – such as phosphorus oxychloride or concentrated sulfuric acid – results in the formation of the 1,3,4-thiadiazole ring. This method is widely preferred because of its simplicity, broad substrate compatibility, and satisfactory product yields [4, 5, 7, 14].

Modern synthetic techniques, including microwave-assisted synthesis, have significantly improved reaction efficiency by reducing reaction time and increasing product yield. In addition, green synthetic approaches employing environmentally friendly solvents, recyclable catalysts, solvent-free conditions, and ultrasonic irradiation have gained increasing attention. These sustainable methods minimize waste generation, reduce energy consumption, and support environmentally responsible pharmaceutical research. [5, 14, 16]

MECHANISM OF THIADIAZOLE RING FORMATION

The formation of the 1,3,4-thiadiazole ring from acyl thiosemicarbazide intermediates proceeds through a sequence of cyclization and dehydration reactions under acidic conditions. Initially, activation of the carbonyl group increases its electrophilic nature, facilitating intramolecular nucleophilic attack by the adjacent nitrogen atom. This interaction leads to the formation of a cyclic intermediate [4, 5, 14].


Subsequent intramolecular rearrangement and elimination of a water molecule promote ring closure and aromatization, resulting in the stable 1,3,4-thiadiazole nucleus. The efficiency of this transformation is influenced by reaction temperature, solvent system, acidity, reaction time, and the electronic characteristics of substituents present in the molecule [4, 5, 14].

Electron-withdrawing substituents generally favor cyclization by stabilizing reaction intermediates and enhancing electrophilic activation, thereby improving reaction efficiency and product yield. A clear understanding of this mechanism is valuable for optimizing synthetic procedures and designing structurally diverse thiadiazole derivatives with enhanced anticancer potential [5, 6, 14].

The proposed cyclization pathway for the formation of the 1,3,4-Thiadiazole ring is presented in Mechanism 1.

The major factors influencing Thiadiazole ring formation are summarized in Figure 3.

Stepwise Mechanism of Acyl Thiosemicarbazide Cyclization to 1,3,4-Thiadiazole



Mechanism 1. Stepwise mechanism of acyl thiosemicarbazide cyclization to 1,3,4-Thiadiazole.




Figure 3. Factors influencing Thiadiazole ring formation.

STRUCTURE–ACTIVITY RELATIONSHIP (SAR) OF 1,3,4-THIADIAZOLE DERIVATIVES

Structure–Activity Relationship (SAR) studies are essential for understanding how structural modifications influence the biological activity of 1,3,4-thiadiazole derivatives. The nature and position of substituents attached to the thiadiazole nucleus play a significant role in determining anticancer potency, selectivity, and pharmacokinetic behavior [1, 2, 5, 15].

Electron-withdrawing substituents, including fluorine, chlorine, bromine, nitro, and trifluoromethyl groups, generally enhance anticancer activity by improving receptor binding affinity, lipophilicity, and metabolic stability. In contrast, electron-donating groups – such as methoxy, hydroxy, amino, and methyl substituents – may improve aqueous solubility, hydrogen-bonding interactions, and target selectivity. The biological activity is also influenced by the substitution pattern, with para-substituted aromatic derivatives frequently exhibiting superior activity compared to ortho- or meta-substituted analogues [1, 6, 10–15].

Molecular hybridization has emerged as an effective strategy for enhancing the therapeutic potential of 1,3,4-thiadiazole derivatives. Hybrid molecules containing quinoline, coumarin, benzimidazole, triazole, pyrazole, or chalcone moieties often demonstrate improved cytotoxicity, enhanced target selectivity, and reduced drug resistance [1, 8, 10, 15–17].

Several thiadiazole derivatives have also shown promising activity against important molecular targets such as EGFR, VEGFR, HDACs, PI3K, topoisomerases, and tubulin proteins. These compounds exert their anticancer effects through multiple mechanisms, including apoptosis induction, inhibition of angiogenesis, disruption of microtubule formation, and cell-cycle arrest. Overall, SAR-guided optimization continues to support the development of more potent and selective thiadiazole-based anticancer agents [1, 6–18].

CONCLUSION

The 1,3,4-thiadiazole scaffold remains one of the most promising heterocyclic frameworks in anticancer drug discovery because of its favorable structural, electronic, and pharmacological properties. Rational structural modification, molecular hybridization, and target-oriented drug design have enabled the development of numerous derivatives with enhanced anticancer activity and improved selectivity.

Advances in synthetic methodologies and characterization techniques have facilitated the preparation of structurally diverse thiadiazole derivatives with significant activity against a wide range of cancer cell lines. These compounds exhibit their therapeutic effects through multiple mechanisms, including apoptosis induction, inhibition of receptor tyrosine kinases, suppression of angiogenesis, cell-cycle arrest, and modulation of critical intracellular signaling pathways.

Emerging approaches – such as molecular docking, artificial intelligence-assisted drug design, and nanotechnology-based drug delivery systems – are expected to accelerate the discovery and optimization of novel thiadiazole-based therapeutics. Continued interdisciplinary research integrating medicinal chemistry, computational modeling, pharmacology, and molecular biology will further strengthen the clinical potential of this scaffold. Therefore, 1,3,4-thiadiazole derivatives continue to represent valuable lead molecules for the development of safer and more effective anticancer drugs.

REFERENCES

1. Indelicato S, Bongiorno D, Mauro M, Cascioferro S. Recent developments of 1,3,4-thiadiazole compounds as anticancer agents. *Pharmaceuticals (Basel)*. 2025;18(4):580. doi: 10.3390/ph18040580.
2. Janowska S, Paneth A, Wujec M. Cytotoxic properties of 1,3,4-thiadiazole derivatives—A review. *Molecules*. 2020;25(18):4309. doi: 10.3390/molecules25184309.

3. Jampilek J. Heterocycles in medicinal chemistry. *Molecules*. 2019;24:3839. doi: 10.3390/molecules24213839.
4. Li Y, Geng J, Liu Y, Yu S, Zhao G. Thiadiazole—A promising structure in medicinal chemistry. *ChemMedChem*. 2013;8(1):27–41. doi: 10.1002/cmdc.201200355.
5. Kumar D, Kumar H, Kumar V, Deep A, Sharma A, Marwaha MG, et al. Mechanism-based approaches of 1,3,4-thiadiazole scaffolds as potent enzyme inhibitors for cytotoxicity and antiviral activity. *Med Drug Discov*. 2023;17:100150. doi: 10.1016/j.medidd.2022.100150.
6. El-Masry RM, Essa BM, Selim AA, El-Emam SZ, Mohamed KO, Sakr TM, et al. New 5-aryl-1,3,4-thiadiazole-based anticancer agents: Design, synthesis, in vitro biological evaluation and in vivo radioactive tracing studies. *Pharmaceuticals (Basel)*. 2022;15:1476. doi: 10.3390/ph15121476.
7. Abouzeid AS, Al-Humaidi TY, Bazaid AS, Qanash H, Binsaleh NK, Alamri A, et al. Synthesis, molecular docking study, and cytotoxicity evaluation of some novel 1,3,4-thiadiazole as well as 1,3-thiazole derivatives bearing a pyridine moiety. *Molecules*. 2022;27:6368. doi: 10.3390/molecules27196368.
8. Alsehli M, Aljuhani A, Ihmaid SK, El-Messery SM, Othman DIA, El-Sayed AAAA, et al. Design and synthesis of benzene homologues tethered with 1,2,4-triazole and 1,3,4-thiadiazole motifs revealing dual MCF-7/HepG2 cytotoxic activity with prominent selectivity via histone demethylase LSD1 inhibitory effect. *Int J Mol Sci*. 2022;23:8796. doi: 10.3390/ijms23158796.
9. Kang JX, Li C, Cheng YM, Huang MX, Zhao GK, Jin ZL, et al. Advances in small-molecule dual inhibitors targeting EGFR and HER2 receptors as anticancer agents. *Curr Med Chem*. 2024. doi: 10.2174/0109298673308896240528173317.
10. Li XY, Wang DP, Li S, Xue WH, Qian XH, Liu KL, et al. Discovery of N-(1,3,4-thiadiazol-2-yl) benzamide derivatives containing a 6,7-methoxyquinoline structure as novel EGFR/HER2 dual-target inhibitors against cancer growth and angiogenesis. *Bioorg Chem*. 2022;119:105469. doi: 10.1016/j.bioorg.2021.105469.
11. Serag MI, Tawfik SS, Eisa HM, Badr SMI. Design, synthesis, biological evaluation and molecular docking study of new 1,3,4-thiadiazole-based compounds as EGFR inhibitors. *Drug Dev Res*. 2025;86:e70035. doi: 10.1002/ddr.70035.
12. Hekal MH, Farag PS, Hemdan MM, El-Sayed AA, Hassaballah AI, El-Sayed WM. New 1,3,4-thiadiazoles as potential anticancer agents: Pro-apoptotic, cell cycle arrest, molecular modelling, and ADMET profile. *RSC Adv*. 2023;13:15810–15825. doi: 10.1039/D3RA02716C.
13. Żurawska K, Stokowy M, Kapica P, Olesiejuk M, Kudelko A, Papaj K, et al. Synthesis and preliminary anticancer activity assessment of N-glycosides of 2-amino-1,3,4-thiadiazoles. *Molecules*. 2021;26:7245. doi: 10.3390/molecules26237245.
14. Stecoza CE, Nitulescu GM, Draghici C, Caproiu MT, Hanganu A, Olaru OT, et al. Synthesis of 1,3,4-thiadiazole derivatives and their anticancer evaluation. *Int J Mol Sci*. 2023;24:17476. doi: 10.3390/ijms242417476.
15. Janowska S, Khylyuk D, Bielawska A, Szymanowska A, Gornowicz A, Bielawski K, et al. New 1,3,4-thiadiazole derivatives with anticancer activity. *Molecules*. 2022;27:1814. doi: 10.3390/molecules27061814.
16. Oubella A, Bimoussa A, Rehman MT, AlAjmi MF, Auhmani A, Taha ML, et al. Molecular hybrids based on 1,2,3-triazole and 1,3,4-thiadiazole cores: Synthesis, characterization, anticancer activity and in silico study. *J Mol Struct*. 2024;1311:138339. doi: 10.1016/j.molstruc.2024.138339.
17. Cascioferro S, Li Petri G, Parrino B, El Hassouni B, Carbone D, Arizza V, et al. 3-(6-Phenylimidazo[2,1-b][1,3,4]thiadiazol-2-yl)-1H-indole derivatives as new anticancer agents in the treatment of pancreatic ductal adenocarcinoma. *Molecules*. 2020;25:329. doi: 10.3390/molecules25020329.
18. Noce B, Di Bello E, Fioravanti R, Mai A. LSD1 inhibitors for cancer treatment: Focus on multi-target agents and compounds in clinical trials. *Front Pharmacol*. 2023;14:1120911. doi: 10.3389/fphar.2023.1120911.